Social Action For Health
Private, Limited by guarantee, no share capital, use of 'Limited' exemption · London
ActiveUnited KingdomIncorporated 1994Private, Limited by guarantee, no share capital, use of 'Limited' exemption
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
No electronic account filings
No extracted electronic accounts are available in our records.
Registered details
02954744- Status
- Active
- Type
- Private, Limited by guarantee, no share capital, use of 'Limited' exemption
- Incorporated
- 1994-08-02
- Jurisdiction
- —
- Registered office
- BRADY ARTS CENTRE, 192-196 HANBURY STREET, LONDON, E1 5HU, ENGLAND
Classification
1 SIC codes53103
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
0 SH01-derived roundsNo reconstructed allotment rounds.
Research and innovation
5 matched grantsGenes & Health Longitudinal Population StudyActiveMRC · Research Grant · 2023-04-16 – 2028-04-15 · with 24 other participants£2,033,056whole project
Genes & Health Longitudinal Population StudyActive
MRC · Research Grant · 2023-04-16 – 2028-04-15 · with 24 other participants
£2,033,056
whole project
Queen Mary University Of LondonleadAston UniversityAstrazenecaBradford Institute for Health Research (BIHR)Bradford Teaching Hospitals NHS Foundation TrustBristol-Myers SquibbCentre of the CellCouncil of Scientific and Industrial Research (CSIR)GlaxoSmithKline (GSK)KEM Hospital, PuneKing'S College LondonLondon Borough of Waltham ForestLondon School of Hygiene and Tropical Medicine (LSHTM)Maze TherapeuticsMerckNovo NordiskPfizer IncSocial Action for HealthTakeda Pharmaceutical CompanyUniversity of CambridgeUniversity Of CambridgeUniversity of ExeterUniversity Of ExeterUniversity Of ManchesterWellcome Sanger Institute
Genes & Health Longitudinal Population StudyActiveMRC · Research Grant · 2023-04-16 – 2028-04-15 · with 24 other participants£2,033,056whole project
Genes & Health Longitudinal Population StudyActive
MRC · Research Grant · 2023-04-16 – 2028-04-15 · with 24 other participants
£2,033,056
whole project
Queen Mary University Of LondonleadAston UniversityAstrazenecaBradford Institute for Health Research (BIHR)Bradford Teaching Hospitals NHS Foundation TrustBristol-Myers SquibbCentre of the CellCouncil of Scientific and Industrial Research (CSIR)GlaxoSmithKline (GSK)KEM Hospital, PuneKing'S College LondonLondon Borough of Waltham ForestLondon School of Hygiene and Tropical Medicine (LSHTM)Maze TherapeuticsMerckNovo NordiskPfizer IncSocial Action for HealthTakeda Pharmaceutical CompanyUniversity of CambridgeUniversity Of CambridgeUniversity of ExeterUniversity Of ExeterUniversity Of ManchesterWellcome Sanger Institute
Physical and mental health multimorbidity across the lifespan (LIfespaN multimorbidity research Collaborative (LINC)).SPF · Research Grant · 2021-12-01 – 2026-03-30 · with 27 other participants£3,034,322whole project
Physical and mental health multimorbidity across the lifespan (LIfespaN multimorbidity research Collaborative (LINC)).
SPF · Research Grant · 2021-12-01 – 2026-03-30 · with 27 other participants
£3,034,322
whole project
Cardiff UniversityleadAlan Turing InstituteAston UniversityAstrazenecaBradford Institute for Health Research (BIHR)Bristol-Myers SquibbCardiff UniversityCentre of the CellEast London Genes and HealthGlaxoSmithKline (GSK)Imperial College LondonKing'S College LondonMaze TherapeuticsMerckNational Center for Mental Health (NCMH)Newcastle UniversityNorwegian Institute of Public HealthNorwegian Mother and Child Cohort (MoBa)Novo NordiskPfizer IncSocial Action for HealthTakeda Pharmaceutical CompanyThe Lundbeck Foundation Initiative for Integrative Psychiatric ResearchUniversity of BristolUniversity of CambridgeUniversity Of EdinburghUniversity Of ManchesterWellcome Sanger Institute
Investigating five large population-based cohort studies to understand for the precursors of multimorbidity risk.SPF · Research Grant · 2020-08-31 – 2021-02-28 · with 38 other participants£74,159whole project
Investigating five large population-based cohort studies to understand for the precursors of multimorbidity risk.
SPF · Research Grant · 2020-08-31 – 2021-02-28 · with 38 other participants
£74,159
whole project
Cardiff UniversityleadAlan Turing InstituteAston UniversityAstrazenecaBradford Institute for Health Research (BIHR)Bradford Metropolitan District CouncilBristol-Myers SquibbCardiff UniversityCentre of the CellCouncil of Scientific and Industrial Research (CSIR)Department For EducationEast London Genes and HealthEuropean Cooperation in Science and Technology (COST)GlaxoSmithKline (GSK)Imperial College LondonKEM Hospital, PuneLondon School of Hygiene and Tropical Medicine (LSHTM)Maze TherapeuticsMerckMinistry of Housing, Communities and Local GovernmentNational Center for Mental Health (NCMH)National Institutes of Health (NIH)Newcastle UniversityNorwegian Institute of Public HealthNorwegian Mother and Child Cohort (MoBa)Novo NordiskPfizer IncSocial Action for HealthStanford MedicineTakeda Pharmaceutical CompanyThe Lundbeck Foundation Initiative for Integrative Psychiatric ResearchUniversity College LondonUniversity Of BirminghamUniversity of BristolUniversity of CambridgeUniversity of ExeterUniversity Of ManchesterUniversity Of NottinghamWellcome Sanger Institute
Multimorbidity clusters, trajectories and genetic risk, in British south AsiansMRC · Research Grant · 2020-03-01 – 2023-05-30 · with 22 other participants£505,647whole project
Multimorbidity clusters, trajectories and genetic risk, in British south Asians
MRC · Research Grant · 2020-03-01 – 2023-05-30 · with 22 other participants
£505,647
whole project
Queen Mary University Of LondonleadAlan Turing InstituteAston UniversityAstrazenecaBradford Institute for Health Research (BIHR)Bristol-Myers SquibbCentre of the CellCouncil of Scientific and Industrial Research (CSIR)GlaxoSmithKline (GSK)KEM Hospital, PuneLondon School of Hygiene and Tropical Medicine (LSHTM)Maze TherapeuticsMerckNational Institute for Health and Care ResearchNewcastle UniversityNovo NordiskPfizer IncSocial Action for HealthTakeda Pharmaceutical CompanyUniversity of CambridgeUniversity of ExeterUniversity Of ManchesterWellcome Sanger Institute